HTA Council Recommendation (as of 13 June 2025) The HTA Council positively recommends the government financing of both live, attenuated, recombinant, vero cell; and, inactivated adsorbed, vero cell Japanese Encephalitis vaccines to be rolled out in high risk areas (as defined by DOH), contingent on the budget and resource availability. (See below for more details) continue reading : Japanese Encephalitis Vaccine for the prevention of japanese encephalitis among children 9 to 59 months old in high-risk areas
Pneumococcal Conjugate Vaccine (PCV) for Infants less than 1 year old and children aged 13 to 23 months for catch-up immunization
HTA Council Recommendation (as of 16 May 2025) The HTA Council positively recommends the government financing of the following PCVs for infants less than 1 year old and children aged 13 to 23 months, in no particular order: Recommending the above-mentioned vaccines will provide the National Immunization Program (NIP) more options and more flexibility in continue reading : Pneumococcal Conjugate Vaccine (PCV) for Infants less than 1 year old and children aged 13 to 23 months for catch-up immunization
Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine as an active booster immunization against tetanus, diphtheria and pertussis
HTA Council Final Recommendation (as of 26 May 2025) The HTA Council positively recommends the government financing of Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine for the following populations: Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
CoronaVac COVID-19 Vaccine for Children 6 to 17 Years Old
Date of SOH Approval: 10 October 2022 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of CoronaVac COVID-19 Vaccine for children continue reading : CoronaVac COVID-19 Vaccine for Children 6 to 17 Years Old
Second Booster of COVID-19 Vaccines for the Prevention of COVID-19 Among Individuals Aged 50 Years Old and Older and Individuals with Comorbidities Aged 18 to 49 Years Old
Date of SOH Approval: 26 August 2022 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of Second Booster of COVID-19 vaccines continue reading : Second Booster of COVID-19 Vaccines for the Prevention of COVID-19 Among Individuals Aged 50 Years Old and Older and Individuals with Comorbidities Aged 18 to 49 Years Old